



# ACTAS Derma-Sifiliográficas

Full English text available at  
[www.actasdermo.org](http://www.actasdermo.org)



## REVIEW

### Psoriasis and Nonalcoholic Fatty Liver Disease<sup>☆</sup>



J.M. Carrascosa,<sup>a,\*</sup> C. Bonanad,<sup>b</sup> E. Dauden,<sup>c</sup> R. Botella,<sup>d</sup> A. Olveira-Martín<sup>e</sup>, on behalf of the Systemic Inflammation in Psoriasis Working Group

<sup>a</sup> Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol. Universitat Autònoma de Barcelona, Badadalonga, Spain

<sup>b</sup> Servicio de Cardiología, Hospital Clínico Universitario, Valencia, Spain

<sup>c</sup> Servicio de Dermatología, Hospital La Princesa, Madrid, Spain

<sup>d</sup> Servicio de Dermatología, Hospital Universitario La Fe, Valencia, Spain

<sup>e</sup> Servicio de Aparato Digestivo, Hospital la Paz, Madrid, Spain

Received 21 July 2016; accepted 31 December 2016

Available online 7 June 2017

#### KEYWORDS

Psoriasis;  
Nonalcoholic fatty  
liver disease;  
Steatosis;  
Treatment;  
Biologic agents;  
Methotrexate

**Abstract** Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver condition in the West. The prevalence and severity of NAFLD is higher and the prognosis worse in patients with psoriasis. The pathogenic link between psoriasis and NAFLD is chronic inflammation and peripheral insulin resistance, a common finding in diseases associated with psoriasis. NAFLD should therefore be ruled out during the initial evaluation of patients with psoriasis, in particular if they show signs of metabolic syndrome and require systemic treatment. Concomitant psoriasis and NAFLD and the likelihood of synergy between them place limitations on general recommendations and treatment for these patients given the potential for liver toxicity. As hepatotoxic risk is associated with some of the conventional drugs used in this setting (e.g., acitretin, methotrexate, and ciclosporin), patients prescribed these treatments should be monitored as appropriate. Anti-tumor necrosis factor agents hold the promise of potential benefits based on their effects on the inflammatory process and improving peripheral insulin resistance. However, cases of liver toxicity have also been reported in relation to these biologics. No evidence has emerged to suggest that anti-p40 or anti-interleukin 17 agents provide benefits or have adverse effects.

© 2017 Elsevier España, S.L.U. and AEDV. All rights reserved.

<sup>☆</sup> Please cite this article as: Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martín A, en nombre del Grupo de Trabajo en Inflamación Sistémica en Psoriasis. Psoriasis e hígado graso no alcohólico. Actas Dermosifiliogr. 2017;108:506–514.

\* Corresponding author.

E-mail address: [jmcarrascosac@hotmail.com](mailto:jmcarrascosac@hotmail.com) (J.M. Carrascosa).

**PALABRAS CLAVE**

Psoriasis;  
 Hígado graso no  
 alcohólico;  
 Esteatosis;  
 Tratamiento;  
 Biológicos;  
 Metotrexato

**Psoriasis e hígado graso no alcohólico**

**Resumen** El hígado graso no alcohólico es la principal causa de enfermedad hepática en nuestro medio. Los pacientes con psoriasis presentan mayor prevalencia y gravedad y peor pronóstico de esta hepatopatía. El vínculo patogénico entre ambas es el estado de inflamación crónica y la resistencia periférica a la insulina, habitual en las comorbilidades asociadas a la psoriasis. Por este motivo, en la evaluación de los pacientes con psoriasis, en particular si existen componentes del síndrome metabólico y se requiere tratamiento sistémico, se recomienda descartar esta posibilidad. La coexistencia de psoriasis e hígado graso no alcohólico, con probable sinergia entre ambos, condiciona las medidas generales que deben recomendarse en estos pacientes y también la estrategia terapéutica, por la potencial hepatotoxicidad de algunos de ellos. En este sentido, algunos de los fármacos convencionales habituales como acitretino, metotrexato o ciclosporina presentan potenciales efectos hepatotóxicos cuya repercusión en cada paciente debe evaluarse de forma individualizada. Los fármacos anti-TNF podrían tener efectos beneficiosos fundamentados en el buen control del proceso inflamatorio y de una mejoría de la resistencia periférica a la insulina. Sin embargo, se han descrito casos de hepatotoxicidad en algunos pacientes. No existe evidencia de efectos beneficiosos o perjudiciales de los fármacos anti p40 o anti IL-17.

© 2017 Elsevier España, S.L.U. y AEDV. Todos los derechos reservados.

**Nonalcoholic Fatty Liver Disease: The Concept**

Nonalcoholic fatty liver disease (NAFLD) is a process in which fat is deposited in the liver in the absence of significant alcohol consumption or the use of drugs—such as steroids, methotrexate (MTX), tamoxifen, or amiodarone—that facilitate steatosis.<sup>1</sup> Certain hereditary conditions such as Wilson disease, abetalipoproteinemia, Wolman disease, and cholesteryl ester storage disease are also incompatible with a diagnosis of NAFLD.<sup>1</sup> Once these conditions are excluded, nearly all patients diagnosed with NAFLD share the characteristics associated with metabolic risk, such as obesity, type 2 diabetes mellitus, hypertension, and dyslipidemia. NAFLD and metabolic syndrome share the pathophysiologic mechanism of insulin resistance.<sup>2</sup>

Two histologic forms of the disease can be distinguished: one is steatosis, in which fat has been deposited but liver cells are not yet damaged, and the other is steatohepatitis, which is characterized by liver inflammation that can eventually lead to fibrosis. Mortality is higher in patients with NAFLD than in the general population, regardless of which of these histologic variants is present; the cause of death is usually cardiovascular disease.<sup>3</sup> Because steatohepatitis is an inflammatory condition, the liver is threatened, and 15% to 25% of patients will have progressed to cirrhosis within 10 years. Once cirrhosis develops, complications (liver failure, esophageal varices, and liver cancer) will lead to death in 25% of affected patients within 5 years.<sup>4</sup> Why fat deposition causes inflammation and fibrosis in some patients but not others is poorly understood, although genetic and environmental factors are probably both relevant.<sup>5</sup>

NAFLD is important in the West because it is currently the most prevalent liver disorder. Approximately 20% of adults in the general population have NAFLD, and among them about 20% have the aggressive form, steatohepatitis.<sup>6</sup> The prevalence is much higher among adults with metabolic syndrome, where 38% of overweight persons (with a body mass index

[BMI] between 25 and 30) have NAFLD. The prevalence rates in obese (BMI, 30–40) and severely obese (BMI, 40–45) persons are 46% and 65%, respectively. Finally, some 90% of morbidly obese patients (BMI > 45) have this condition, and 5% of them have cirrhosis. Among diabetics, the prevalence is 69%, and among patients with elevated triglyceride levels, 50%.<sup>7</sup> A sign of the seriousness of this situation is that nonalcoholic steatohepatitis is currently the second most common cause of liver transplantation in the United States, and it is expected to become the first cause in the coming years.<sup>8</sup>

In spite of these statistics, NAFLD is clearly underdiagnosed because there are no signs or symptoms that arouse suspicion except when the disease becomes advanced and also because serum biochemical markers show only slight, nonspecific changes; results may even stay within the normal limits in 15% to 39% of patients.<sup>9,10</sup>

A diagnosis of NAFLD requires evidence of steatosis by liver biopsy or imaging and the exclusion of alcohol consumption or other general causes of liver disease or conditions that lead to steatosis.<sup>1</sup> The first criterion—evidence of steatosis—is critical. The list of causes of liver disease are well established<sup>11</sup> while the alternative causes of steatosis are very rare and, in principle, relatively easy to identify. A liver biopsy is the gold standard, but it is invasive, has associated risk of complications and death, and is costly.<sup>12</sup> Furthermore, it is not reasonable or even feasible to biopsy 20% of the population. Interest in finding a non-invasive approach to diagnosis is therefore growing. A fatty liver is usually detected through imaging (ultrasound, computed tomography scans, or nuclear magnetic resonance); the sensitivity and specificity of images are 60% and 94%, respectively.<sup>13,14</sup> Ultrasound is usually chosen because it is innocuous and widely available.<sup>1</sup> However, neither liver enzymes nor images can distinguish between steatosis and steatohepatitis. Nor can they establish or rule out the presence of fibrosis. Various scoring systems using the results of serum tests have therefore been developed. The most

**Table 1** Formula for the NAFLD Fibrosis Score and Risk Interpretation<sup>a</sup>

NAFLD Fibrosis Score =  $-1.675 + 0.037 \times \text{age in y} + 0.094 \times \text{BMI (kg/m}^2) + 1.13 \times \text{glucose intolerance or diabetes (yes = 1, no = 0)} + 0.99 \times \text{AST/ALT ratio} - 0.013 \times \text{platelet count (} \times 10^9/\text{L)} - 0.66 \times \text{albumin (g/dL)}$

Calculator available from: <http://nafldscore.com>

A score  $< -1.455$  predicts low risk for advanced fibrosis.

A score  $> 0.676$  predicts advanced fibrosis.

Risk is indeterminate if the score falls between  $-1.455$  and  $0.676$ .

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; NAFLD, nonalcoholic fatty liver disease.

<sup>a</sup> Adapted from Angulo et al.<sup>15</sup>

widely accepted is the NAFLD fibrosis score,<sup>15</sup> which is calculated according to a formula (<http://nafldscore.com>) based on easy-to-obtain measurements: BMI; age; platelet count; and serum albumin, aspartate transaminase (AST), and alanine transaminase (ALT) (Table 1). Moreover, this score is highly sensitive (67%) and specific (60%) for excluding (67%) or detecting (97%) the presence of advanced fibrosis using an area under the receiver operating characteristic curve of 0.85 as the cutoff. The severity of liver damage can also potentially be assessed by measuring liver stiffness indirectly with elastography. The usefulness of this approach would mainly be to identify patients at low risk of advanced fibrosis or cirrhosis given the test's lack of precision when disease is advanced.<sup>16</sup>

The European Association for the Study of the Liver, the European Association for the Study of Diabetes, and the European Association for the Study of Obesity have recently published new joint guidelines for managing NAFLD.<sup>17</sup> They recommend that all patients with insulin resistance or risk factors for metabolic syndrome be screened for NAFLD by ultrasound and liver biochemistry. Any increase in AST, ALT, and/or  $\gamma$ -glutamyltransferase are relevant, regardless of magnitude. The screening algorithm is shown in Fig. 1.<sup>17</sup>

### Therapeutic Management of NAFLD

At this time there is no specific treatment for NAFLD available. Weight loss of at least 7% to 10% and exercise are associated with histologic improvement,<sup>18</sup> but they are difficult to achieve and particularly difficult to maintain long-term. Alcohol, saturated fats, and fructose-sweetened beverages should be avoided.<sup>19</sup> Coffee consumption, on the other hand, can be recommended.<sup>20</sup> Several drugs (metformin, pioglitazone, eicosapentenoic acid, statins, and vitamin E) have been tried, but there is a lack of sufficient evidence on which to base a strong recommendation.<sup>1,6,21-24</sup>

### NAFLD and Psoriasis

The first observational studies showing an association between NAFLD and psoriasis began to appear during


the last 10 years,<sup>25,26</sup> and the association has since been confirmed.<sup>27,28</sup> Gisondi et al.<sup>25</sup> saw a higher rate of ultrasound-diagnosed NAFLD (47%) in a series of 130 consecutive patients with psoriasis than in 260 healthy controls (28%) matched for age, sex, and BMI. The psoriasis patients were also more likely to have metabolic syndrome and higher C-reactive protein levels; those who also had NAFLD had higher interleukin (IL) 6 and lower adiponectin levels than those without the disease. Abedini et al.<sup>28</sup> reported finding NAFLD in 65.6% of patients with psoriasis (vs 35% of healthy controls), and van der Voort et al.<sup>27</sup> found that 46.2% of psoriatic patients and 33.3% of controls had NAFLD in a population-based series of 2292 persons over the age of 55 years in Rotterdam. These findings may be attributable to the association between psoriasis and metabolic syndrome, given that the conditions defining the latter are those that lead to NAFLD.<sup>29</sup> Miele et al.<sup>26</sup> studied a cohort of psoriasis patients with and without NAFLD, finding that NAFLD was also associated with psoriatic arthritis. Roberts et al.<sup>30</sup> reported finding a relationship between greater severity of psoriasis and NAFLD. Specifically, they saw steatohepatitis in 22% of the patients with both psoriasis and NAFLD who underwent liver biopsy. The NAFLD patients with steatohepatitis were also more likely to be obese and have higher insulin and transaminase levels; they also found marked differences in risk for NAFLD according to ethnic origin. Similarly, van der Voort et al.<sup>27</sup> found that patients of Latin American origin carried greater risk (83%), followed by Caucasians (39%), and finally African Americans (33%).

### Clinical Suspicion and Screening for NAFLD in Dermatology

A high index of suspicion concerning NAFLD is needed in dermatology because most cases encountered will be asymptomatic. The dermatologist should above all be aware of the high prevalence in patients with psoriasis. It is also important to note signs of the components of metabolic syndrome: diabetes mellitus, obesity, dyslipidemia, and hypertension. Abnormal liver enzymes may be difficult to discern because elevations are usually slight, at less than 2- to 3-fold the normal values and with an ALT/AST ratio greater than 1; alkaline phosphatase and  $\gamma$ -glutamyltransferase are occasionally elevated.<sup>31</sup> Liver enzymes can be normal in 15% to 30% or more of patients with NAFLD,<sup>10</sup> even though 35% of such patients have advanced fibrosis or cirrhosis. Given this situation, in the presence of the most prevalent indicator of risk for NAFLD—namely components of metabolic syndrome—ultrasound imaging to rule out liver disease is indicated even when biochemistry is normal.<sup>17</sup> At this time, however, the clinical algorithm recommended by most medical associations specializing in NAFLD (Fig. 1), does not recognize the need for imaging to evaluate patients with psoriasis in the absence of liver enzyme abnormalities.

Once NAFLD has been confirmed, the dermatologist must cooperate in prescribing the necessary dietary measures and adjusting drug dosages if transaminase levels are elevated.

The absence of liver damage according to the initial assessment does not exclude its development over the coming years. Therefore, patients will have to be reassessed if



**Figure 1** Nonalcoholic fatty liver disease (NAFLD) in patients with psoriasis. Adapted from clinical guidelines.<sup>17</sup>

<sup>a</sup> Aspartate transaminase (ASP), alanine transaminase (ALT), and  $\gamma$ -glutamyltransferase (GGT).

<sup>b</sup> Any increase in ASP, ALT, and/or GGT.

analyses reveal signs of damage or if metabolic syndrome develops.<sup>17</sup>

### Pathogenesis of NAFLD in Psoriasis

This review does not attempt to delve deeply into the pathogenesis of NAFLD, but it is useful to be aware of the two-hit hypothesis.<sup>32</sup> In this theory, the first phase would be marked by the abnormal accumulation of triglycerides in liver cells, a development in which insulin resistance plays a large role. In the second phase, the steatotic liver appears to become susceptible to injury induced by several players and events involving various adipokines and oxidative stress in the endoplasmic reticulum, as well as mitochondrial dysfunction and liver apoptosis. These events favor the transition from simple steatosis to steatohepatitis. Besides the involvement of insulin resistance in both these phases of progression toward NAFLD—as well as in the induction and activation of profibrotic cytokines—other chronic inflammatory processes that might be present, such as psoriasis, can contribute proinflammatory cytokines.<sup>33</sup> Thus, the pathogenic relationship between NAFLD and psoriasis is complex and probably multifactorial, although it is presumably related to a state of chronic underlying inflammation.

NAFLD and psoriasis are probably linked partly because some of the conditions that often accompany psoriasis are also the ones that cause NAFLD. Among them, obesity stands out. The epidemiologic association between obesity and psoriasis is clear, particularly in severe psoriasis, and the influences probably operate in both directions, such that obesity favors psoriasis and vice versa.<sup>34</sup> The prevalence of

NAFLD is also clearly higher in obese patients, especially those with excess abdominal fat, which is more metabolically active than subcutaneous fat.<sup>35</sup> Obesity is associated with risk for developing insulin resistance, the main factor in the development of NAFLD.<sup>36</sup> Excessive fat deposition leads to an imbalance between pro- and anti-inflammatory cytokines, favoring the progression of liver disease. When adipose tissue secretes an abundance of adipokines—tumor necrosis factor (TNF), IL-6, leptin, visfatin, or resistin—a proinflammatory state may develop in psoriatic skin as the result of the proliferation of keratinocytes, angiogenesis, the response of type 1 T cells, or the expression of adhesion molecules. This state may also be expressed in NAFLD, contributing to insulin resistance or liver fibrosis. In addition, there is also a decrease in the concentration of adipokines that protect against inflammation—such as adiponectin, a promoter of skin anti-inflammatory cytokines that enhances insulin sensitivity.<sup>37</sup>

The involvement of IL-17 in both psoriasis and NAFLD is interesting. T cells in adipose tissue synthesize IL-17, which is able to regulate adipogenesis and glucose metabolism. Type 17 T helper cells and IL-17 could facilitate the progression from simple steatosis to steatohepatitis.<sup>38</sup>

### Implications for the Management of Conventional Systemic Treatments

The high prevalence of NAFLD in psoriasis leads to therapeutic concerns because this chronic skin disease must be treated over decades.

**Table 2** Main Findings of Studies on the Prevalence and Features of NAFLD in Psoriasis.

Authors	Study Population	Psoriasis, n	No Psoriasis, n	Findings	Ethnicity
Roberts et al. <sup>30</sup>	Patients with psoriasis or psoriatic arthritis	103	–	NAFLD prevalence, 47%. Steatohepatitis in 22% of patients with NAFLD.	Caucasians, Latin Americans, African Americans, Asians
Gisondi et al. <sup>25</sup>	Hospitalized dermatology patients; controls, hospital staff	130	260	NAFLD prevalence higher in psoriasis patients (47%) than controls (28%) ( $P < .0001$ ). Metabolic syndrome and elevated CRP levels more prevalent in patients with psoriasis and NAFLD ( $n = 61$ ), who also had higher mean (SD) PASI levels: 14.2 (12.6) vs 9.6 (7.4) for patients without NAFLD ( $n = 69$ ) ( $P < .01$ ).	Not reported (Caucasians?)
Miele et al. <sup>26</sup>	Patients with psoriasis; patients with NAFLD without psoriasis	142	125	59.2% were diagnosed with NAFLD. Metabolic syndrome, obesity, dyslipidemia, elevated AST/ALT ratio, and psoriatic arthritis frequencies were higher in patients with both psoriasis and NAFLD. NAFLD patients with psoriasis had more severe liver disease than patients without psoriasis.	Not reported (Caucasians?)
Abedini et al. <sup>28</sup>	Patients with psoriasis vs healthy controls	123	123	Prevalence of NAFLD was higher in psoriasis patients (65.6% vs 35% in controls) ( $P < .01$ , OR = 3.53). Moderately severe NAFLD (grade 2) was more common than mild NAFLD (grade 1) ( $P < .01$ ) in psoriasis patients. Higher rates of hypertension (16.5%), altered liver function (16.4%), and metabolic syndrome (46.6%) also found in patients with psoriasis and NAFLD.	Not reported (Caucasians?)
van der Voort et al. <sup>27</sup>	Patients >55 years with NAFLD and psoriasis vs NAFLD patients without psoriasis	118	2174	46.2% had NAFLD and psoriasis; 33%, only NAFLD. Psoriasis continued to be a predictor of NAFLD after controlling for alcohol consumption, ALT level, and presence of metabolic syndrome.	95% Caucasian

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; PASI, Psoriasis Area and Severity Index.

The incidence of MTX-induced liver damage is known to be higher in psoriasis<sup>39</sup> than in other chronic inflammatory diseases. A recent retrospective study saw, for example, that 58% of 710 patients on MTX for psoriasis had elevated transaminase levels.<sup>40</sup> In the light of our current understanding, this finding may be relevant to the known association between NAFLD and psoriasis. Given

the high rates of both NAFLD and steatohepatitis in this setting, we should rule out significant steatosis before starting MTX, at least in patients with signs of metabolic syndrome. In addition to ultrasound screening, two new tools, the FibroTest and the FibroScan (liver elastography) may be useful for assessing liver fibrosis.<sup>41</sup>

MTX toxicity presents with histologic findings and may therefore reflect pathogenic mechanisms that are different from those associated with NAFLD. However, the shared risk factors that aggravate both MTX toxicity and NAFLD—such as obesity, diabetes, or hyperlipidemia—are observed often in patients with severe psoriasis.<sup>42</sup>

Liver toxicity is also among the potential adverse effects of ciclosporin. The effect may be direct or it may be a byproduct of a deteriorating lipid profile.<sup>43</sup> Acitretin can also raise triglyceride levels and has been associated with transaminase elevations in 1 out of 4 patients, although tissue damage following intermittent use of the drug has not been reported.<sup>44</sup>

## Biologic Agents in Patients With Psoriasis and NAFLD

TNF plays a central role in the inflammatory process in NAFLD, as in other chronic inflammatory diseases.<sup>45</sup> In fact, TNF has been studied for its potential use as a diagnostic and prognostic tool in NAFLD.<sup>46</sup> Given the pathogenic role of this cytokine, anti-TNF agents such as infliximab and adalimumab have also been tried in this setting<sup>47,48</sup> because of improvements observed in liver and metabolic biomarkers after biologic therapy for other inflammatory diseases.<sup>49,50</sup>

Biologics have a better safety profile than the conventional treatments for NAFLD mentioned earlier. For example, when adalimumab was used for an average of 5 years in 32 patients with liver disease and psoriasis, no cases of liver disease progression or development of liver toxicity were observed.<sup>51</sup>

Biologic therapy could exercise regulatory effects on some adipocytokines. Shibata et al.<sup>52</sup> reported an increase in adiponectin and IL-6 levels during treatment with infliximab, and adalimumab and etanercept may inhibit proinflammatory adipocytokines.<sup>53</sup>

Studies of the impact of anti-TNF agents on the lipid profile, a risk factor for NAFLD, have yielded inconsistent results. While some authors have not been able to demonstrate a significant effect, others have reported elevated triglycerides and lower high-density lipoprotein (HDL) cholesterol levels in patients with infliximab-treated psoriatic arthritis.<sup>54</sup> Etanercept therapy, on the other hand, has favorably modulated the antioxidant and anti-inflammatory properties of HDL cholesterol as well as modulated adipolipoprotein A1 and B levels, reducing lipid peroxidation.<sup>55</sup>

Marra et al.<sup>56</sup> showed improved insulin sensitivity in patients treated with etanercept for psoriasis, an effect that could potentially have a favorable influence on the course of NAFLD.

It must be borne in mind that anti-TNF agents can occasionally induce autoimmune or drug-related hepatitis.<sup>57</sup> The risk is very low, however. Only 20 cases of autoimmune hepatitis have ever been reported; most were mild cases associated with infliximab and responded quickly to steroid treatment.<sup>41</sup> Anti-TNF agents have also been linked to weight gain in psoriasis patients, although the gains have generally been modest. However, long-term use has led to considerable gain in some patients, and this adverse effect

**Table 3** Risk Factors for Metabolic Syndrome<sup>a</sup>

Waist circumference $\geq 94$ cm ( $\sigma$ ), $\geq 80$ cm ( $\varphi$ )
Blood pressure $\geq 130/85$ mm Hg or on antihypertensive treatment
Fasting glucose $\geq 100$ mg/dL or in treatment for type 2 diabetes mellitus
Triglycerides $\geq 150$ mg/dL
HDL cholesterol $< 40$ mg/dL ( $\sigma$ ) or $< 50$ mg/dL ( $\varphi$ )

Abbreviation: HDL, high-density lipoprotein.

<sup>a</sup> Source, joint guidelines of the European Association for the Study of the Liver, the European Association for the Study of Diabetes, and the European Association for the Study of Obesity.<sup>17</sup>

potentially aggravates the obesity associated with severe psoriasis and NAFLD.<sup>58</sup>

High transaminase levels were detected in 6 patients in a series of 44 treated with ustekinumab for an average of 46.7 months.<sup>59</sup> Five of the 6 patients developed hepatotoxicity related to other drugs, 3 developed fatty liver, and 3 were receiving other hepatotoxic drugs while taking ustekinumab. The authors concluded that ustekinumab-related toxicity was mild and uncommon. Hepatotoxicity is not described as a side effect detected in clinical trials of secukinumab<sup>60</sup> (Table 2).

## Conclusions

NAFLD is the most frequent liver disorder in the West (Table 3). Patients with psoriasis have a higher prevalence of NAFLD, a higher rate of severe disease, and a worse prognosis. Dermatologists should routinely evaluate psoriasis patients for NAFLD. The pathogenic links between psoriasis and NAFLD are chronic inflammation and peripheral insulin resistance, which is a common finding in diseases associated with psoriasis. The dermatologist should be aware not only of the high prevalence of NAFLD in psoriasis but also of the possibility of steatohepatitis, especially when psoriasis is severe or when there are signs of metabolic syndrome. Psoriasis patients with insulin resistance or risk factors for metabolic syndrome should be specifically evaluated for fatty liver by abdominal ultrasound and liver biochemistry. Concurrent psoriasis and NAFLD, and the likely synergy between them, affect the general recommendations we can make and the treatment strategies we can adopt. Some drugs carry risk of hepatotoxicity. On the other hand, there is a possibility that achieving good control of inflammation and pathogenic factors associated with NAFLD will improve the prognosis.

## Ethical Disclosures

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this investigation.

**Data confidentiality.** The authors declare that no private patient data are disclosed in this article.

## Key Points

- The incidence of NAFLD is 1.5- to 3-fold higher in psoriasis patients than in the nonpsoriatic population, meaning we can expect to find NAFLD in roughly half of our patients with psoriasis. The prevalence of steatohepatitis is also higher in psoriasis.
- Prognosis in NAFLD is affected by the presence and severity of steatohepatitis and liver fibrosis.
- Abdominal ultrasound screening is recommended in patients with insulin resistance or signs of metabolic syndrome and moderate to severe psoriasis, even in the absence of abnormal liver enzymes.
- Patients with NAFLD should be referred to a specialist for evaluation and follow-up.
- A fatty liver limits therapeutic options and makes it advisable to tailor monitoring in patients taking potentially hepatotoxic drugs.
- Anti-TNF biologics offer theoretical benefits for patients with NAFLD as a result of better control of the inflammatory process and peripheral insulin resistance. Ustekinumab and secukinumab do not seem to affect NAFLD adversely.

**Right to privacy and informed consent.** The authors declare that no private patient data are disclosed in this article.

## Conflicts of Interest

Abbvie sponsored the meetings of the working group, but no employees of the laboratory participated in the research, interpretation, discussion, or drafting of the text.

J. M. Carrascosa has served as a consultant, given invited talks, and/or participated in clinical trials sponsored by the following laboratories: Abbvie, Janssen, Lilly, Pfizer, Novartis, Pfizer, and Celgene.

## References

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. *Hepatology*. 2012;55:2005–23.
2. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. *Dig Liver Dis*. 2015;47:181–90.
3. Byrne CD, Targher G. NAFLD: A multisystem disease. *J Hepatol*. 2015;62 Suppl 1:S47–64.
4. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. *J Gastroenterol Hepatol*. 2009;24:248–54.
5. Higuera-de la Tijera F, Servín-Caamaño AI. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. *World J Hepatol*. 2015;7:1297–301.
6. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. *Aliment Pharmacol Ther*. 2011;34:274–85.
7. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. The prevalence of primary non-alcoholic fatty liver disease in a population based study and its association with biochemical and anthropometric measures. *Liver Int*. 2006;26:856–63.
8. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. *Gastroenterology*. 2015;148:547–55.
9. Ahn JS, Sinn DH, Gwak GY, Kim JM, Kwon CH, Joh JW, et al. Steatosis among living liver donors without evidence of fatty liver on ultrasonography: Potential implications for preoperative liver biopsy. *Transplantation*. 2013;95:1404–9.
10. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. *Hepatology*. 2003;37:1286–92.
11. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Eng J Med*. 2000;342:1266–71.
12. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. *Hepatology*. 2009;49:1017–44.
13. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. *J Hepatol*. 2009;51:433–45.
14. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. *World J Gastroenterol*. 2014;20:7392–402.
15. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A Noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;45:846–54.
16. Castera L, Chan HL, Arrese M, Afdhal N, Bedossa P, Friedrich-Rust M, et al. EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol*. 2015;63:237–64.
17. EASL–EASD–EASO. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64:1388–402.
18. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology*. 2015;149:367–78.
19. Softic S, Cohen DE, Kahn CR. Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. *Dig Dis Sci*. 2016;61:1282–93.
20. Shen H, Rodriguez AC, Shiani A, Lipka S, Shahzad G, Kumar A, et al. Association between caffeine consumption and nonalcoholic fatty liver disease: A systemic review and meta-analysis. *Therap Adv Gastroenterol*. 2016;9:113–20.
21. Lincoff A, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. *JAMA*. 2007;298:1180–8.
22. Malhotra A, Shafiq N, Rajagopalan S, Dogra S, Malhotra S. Thiazolidinediones for plaque psoriasis: A systematic review and meta-analysis. *Evid Based Med*. 2012;17:171–6.
23. Masterton GS, Plevris JN, Hayes PC. Review article: Omega-3 fatty acids—a promising novel therapy for non-alcoholic

- fatty liver disease. *Aliment Pharmacol Ther.* 2010;31:679–92.
24. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT). *JAMA.* 2011;306:1549–56.
  25. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. *J Hepatol.* 2009;51:758–64.
  26. Miele L, Vallone S, Cefalo C, La Torre G, di Stasi C, Vecchio FM, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. *J Hepatol.* 2009;51:778–86.
  27. Van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. *J Am Acad Dermatol.* 2014;70:517–24.
  28. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. *Clin Exp Dermatol.* 2015;40:722–7.
  29. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichen- thal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. *Arch Dermatol Res.* 2006;298:321–8.
  30. Roberts KK, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care derma- tology and rheumatology clinic. *Aliment Pharmacol Ther.* 2015;41:293–300.
  31. Daudén E, Castañeda S, Suárez C, García-Campayo J, Blasco AJ, Aguilar MD, et al. Integrated approach to comorbidity in patients with psoriasis. *Actas Dermosifiliogr.* 2012;103 Suppl 1:1–64.
  32. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med.* 2002;346:1221–31.
  33. Downman JK, Tomlinson JW, Newsome PN. Pathogenesis of non- alcoholic fatty liver disease. *QJM.* 2010;103:71–83.
  34. Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, et al. BIOBADADERM Study Group. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobada- derm Registry. *J Eur Acad Dermatol Venereol.* 2014;28: 907–14.
  35. Koppe SW. Obesity and the liver: Nonalcoholic fatty liver dis- ease. *Transl Res.* 2014;164:312–22.
  36. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. *Mol Cell Endocrinol.* 2010;316:129–39.
  37. Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. *World J Hepatol.* 2015;27:315–26.
  38. Tang Y, Bian Z, Zhao L, Liu Y, Liang S, Wang Q, et al. Interleukin-17 exacerbates hepatic steatosis and inflamma- tion in non-alcoholic fatty liver disease. *Clin Exp Immunol.* 2011;166:281–90.
  39. Taylor WJ, Korendowycz E, Nash P, Helliwell PS, Choy E, Krueger GG, et al. Drug use and toxicity in psoriatic disease: Focus on methotrexate. *J Rheumatol.* 2008;35:1454–7.
  40. Ng LC, Lee YY, Lee CK, Wong SM. A retrospective review of methotrexate-induced hepatotoxicity among patients with psoriasis in a tertiary dermatology center in Malaysia. *Int J Dermatol.* 2013;52:102–5.
  41. Berends MA, Snoek J, de Jong EM, Van Krieken JH, de Knecht RJ, van Oijen MG, et al. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasispatients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. *Liver Int.* 2007;27: 639–45.
  42. Wenk KS, Arrington KC, Ehrlich A. Psoriasis and non- alcoholic fatty liver disease. *J Eur Acad Dermatol Venereol.* 2011;25:383–91.
  43. Erarslan E, Ekiz F, Uz B, Koca C, Turkcü UO, Bayrak R, et al. Effects of erdosteine on cyclosporine-A-induced hepatotoxici- ty in rats. *Drug Chem Toxicol.* 2011;34:32–7.
  44. Silva FS, Ribeiro MP, Santos MS, Rocha-Pereira P, Santos- Silva A, Custódio JB. Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transi- tion: Potential mechanisms of hepatotoxicity. *Toxicology.* 2013;306:93–100.
  45. Tilg H, Moschen AR. Relevance of TNF- $\alpha$  gene polymorphisms in nonalcoholic fatty liver disease. *Expert Rev Gastroenterol Hepatol.* 2011;5:155–8.
  46. Zahran WE, Salah El-Dien KA, Kamel PG, El-Sawaby AS. Efficacy of tumor necrosis factor and interleukin-10 analysis in the follow-up of nonalcoholic fatty liver disease progression. *Indian J Clin Biochem.* 2013;28:141–6.
  47. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF- $\alpha$  reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. *Inflammation.* 2008;31:91–8.
  48. Yalcin M, Akarsu M, Celik A, Sagol O, Tunali S, Ertener O, et al. A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis. *Turk J Gastroenterol.* 2014;25 Suppl 1:167–75.
  49. Campanati A, Ganzetti G, Di Sario A, Damiani A, Sandroni L, Rosa L, et al. The effect of etanercept on hepatic fibro- sis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. *J Gastroenterol.* 2013;48: 839–46.
  50. Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). *Z Gastroenterol.* 2008;46:1369–71.
  51. Vilarrasa E, Puig L, Alomar A. Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients. *JEADV.* 2010;24:P013.
  52. Shibata S, Tada Y, Hau C, Tatsuta A, Yamamoto M, Kamata M, et al. Adiponectin as an anti-inflammatory fac- tor in the pathogenesis of psoriasis: Induction of elevated serum adiponectin levels following therapy. *Br J Dermatol.* 2011;164:667–70.
  53. Campanati A, Ganzetti G, Giuliodori K, Marra M, Bonfigli A, Testa R, et al. Serum levels of adipocytokines in psori- asis patients receiving tumor necrosis factor- $\alpha$  inhibitors: Results of a retrospective analysis. *Int J Dermatol.* 2015;54: 839–45.
  54. Cauza E, Cauza K, Hanusch-Enserer U, Etemad M, Dunky A, Kostner K. Intravenous anti TNF- $\alpha$  antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. *Wien Klin Wochenschr.* 2002;114:1004–7.
  55. Puig L, Strohal R, Fuiman J, Pedersen R, Szumski A, Koenig AS, et al. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. *J Dermatolog Treat.* 2014;25:470–81.
  56. Marra M, Campanati A, Testa R, Sirolla C, Bonfigli AR, Franceschi C, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. *Int J Immunopathol Pharmacol.* 2007;20:731–6.
  57. Germano V, Picchianti, Diamanti A, Baccano G, Natale E, Onetti, et al. Autoimmune hepatitis associated with inflix- imab in a patient with psoriatic arthritis. *Ann Rheum Dis.* 2005;64:1519–20.



58. Gisondi P, Conti A, Galdo G, Piaserico S, de Simone C, Girolomoni G. Ustekinumab does not increase body mass index inpatients with chronic plaque psoriasis: A prospective cohort study. *Br J Dermatol*. 2013;168:1124–7.
59. Llamas-Velasco M, Concha-Garzón MJ, García-Diez A, Daudén E. Liver injury in psoriasis patients receiving ustekinumab: A retrospective study of 44 patients treated in the clinical practice setting. *Actas Dermosifiliogr*. 2015;106:470–6.
60. Ficha técnica del producto [consultado 20 Jul 2016]. Available from: [http://www.ema.europa.eu/docs/es\\_ES/document\\_library/EPAR\\_Product\\_Information/human/003729/WC500183129.pdf](http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_Product_Information/human/003729/WC500183129.pdf).